Clinical trials: DENGUE
Malaria, Dengue
Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal
This trial aims to validate a novel clinical care strategy based on a electronic clinical decision support algorithm (CDSA) combined with point of care rapid diagnostic tests by evaluating its impact on antibiotic prescription…
- Conditions
- Malaria, Dengue, Influenza -Like Illness, Diarrhea
- Trial name
- NCT05050825
- Testing
- Patient clinical management based on the CDSA strategy
- Where
- 4 sites in Senegal
- Volunteers
- 470 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Dengue
Homologous Re-infection With Dengue 1 or Dengue 3
Previous studies with one dengue infection in a controlled environment at Upstate generated data that has been important in understanding the clinical signs and symptoms and how a person's body reacts to dengue infection over…
- Trial name
- NCT05967455
- Testing
- Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC), Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
West Nile Virus
Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age
West Nile virus (WNV) is considered an emerging virus in the United States, and infection can lead to severe illness in older adults.
- Trial name
- NCT02186626
- Testing
- WN/DEN4Δ30 Vaccine
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact.
- Trial name
- NCT04273217
- Testing
- AV-1
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AbViro LLC
Dengue
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
Dengue fever, caused by dengue viruses, is a major health problem in the tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00375726
- Testing
- rDEN3/4delta30(ME)
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Dengue viruses infect millions of people throughout the tropics and subtropics each year. The development of a dengue vaccine is an important health priority.
- Trial name
- NCT02392325
- Testing
- rDEN1Δ30, rDEN2Δ30-7169
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Dengue Fever
Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection
This 3-year prospective observational study aims to identify clinical and laboratory risk factors associated with hospitalization in patients with confirmed dengue virus infection.
- Conditions
- Dengue, Dengue Fever, Dengue Fever With Warning Signs
- Trial name
- DENGUE-FACT (NCT07007585)
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Jose Ivan Rodriguez de Molina Serrano
Dengue Virus
Safety and Immune Response to an Investigational Dengue Type 2 Vaccine
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world.
- Trial name
- NCT01073306
- Testing
- Investigational Vaccine for Dengue Virus Subtype 2
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Dengue Fever
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
This is a descriptive prospective community-based seroprevalence study. Primary objective: To determine the prevalence of specific antibodies (immunoglobulin G [IgG]) against dengue in healthy 5 to 10 year-old children in India.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01477671
- Where
- 4 sites in India
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Zika Virus
Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge
Zika virus (ZIKV) is an illness people can get from mosquitoes. The infection is generally mild with symptoms that include a fever, rash, red eyes, and joint pain, though most of those infected have no symptoms.
- Trial name
- NCT06805487
- Testing
- TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
The purpose of this study is to evaluate the safety of and immune response to two doses of a dengue vaccine (TV003) given 6 months apart to healthy adults, adolescents, and children in Thailand.
- Trial name
- NCT02332733
- Testing
- TV003
- Where
- Thailand
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
DENV Without Warning Signs, DENV with Warning Signs
Innovative Multidisciplinary Strategies for Combating Severe Dengue
The goal of this observational study is to identify biomarkers and host factors associated with dengue severity in patients from dengue-endemic regions.
- Conditions
- DENV Without Warning Signs, DENV with Warning Signs, Severe Dengue, Healthy Controls Group - Age and Sex-matched
- Trial name
- COMBAT (NCT06751836)
- Testing
- Infection and no infection
- Where
- 2 sites in Guatemala, India
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Dengue, Antiviral Drugs
Adaptive Dengue Antiviral Platform Trial
This is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection Primary objectives: To determine the antiviral effectiveness of the…
- Trial name
- ADAPT (NCT06551844)
- Testing
- Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg
- Where
- 2 sites in Malaysia, Vietnam
- Volunteers
- 500 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Dengue
Dengue Virus Infection Amongst Patients With Acute Febrile Illness
A prospective observational study that will be conducted in Tangerang Regency, Indonesia with primary objective to determine the clinical characteristics, specific immune responses, and viral serotypes in patients with confirmed…
- Trial name
- NCT06255509
- Where
- Indonesia
- Volunteers
- 400 people
- Sponsor
- Tangerang District Hospital
Dengue Fever With Warning Signs
Phase 3b Trial To Evaluate Safety And Immune Response (Superiority) of a Two-Dose Butantan-DV Regimen And The Standard Single Dose In Dengue-Naive Children/Adolescents and Immune Response (Non-inferiority) in a Manufacturing Facility Change (DEN-06-IB)
This randomized, double-blind, three parallel-group, multicenter, phase 3b trial evaluates the safety and immunogenicity of Butantan-DV. The study compares two primary immunization regimens (Butantan-DV/Butantan-DV vs.
- Trial name
- DEN-06-IB (NCT07712926)
- Testing
- Butantan-DV (IB), Butantan-DV (WuXi)
- Volunteers
- 1,765 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue Fever
Role of Andi-d in Dengue Fever: a Pilot Study
The purpose of this study is evaluate the role of anti-d in dengue fever.
- Trial name
- NCT01443247
- Testing
- anti-d
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Dengue, Pregnancy
Study on the Risks of Symptomatic Dengue on Pregnancy
Dengue fever is the most common arbovirus worldwide (390 million people infected per year) and is a global public health problem.
- Trial name
- ERiDenG (NCT04826081)
- Testing
- data collection
- Where
- France
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Dengue Fever
Clinical Specimens Testing Program of Dengue Antigen Detection Reagents
Dengue virus serological reagent, included antigen and antiserum, is a serum test for identification of serum antibodies to dengue virus.
- Trial name
- NCT01917422
- Where
- Taiwan
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Dengue
Study to Examine the Effects of Oral Fenretinide
This randomized, placebo controlled single center study examines the extent to which 600 mg/m2/day of orally administered ISLA101 (fenretinide), given prophylactically or therapeutically, may reduce or eliminate signs and…
- Trial name
- PROTECT (NCT06528457)
- Testing
- ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Island Pharmaceuticals
Dengue, Dengue Fever
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
The aim of the trial was to assess the efficacy of the CYD dengue vaccine in preventing symptomatic, virologically-confirmed dengue (VCD) cases.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01373281
- Testing
- Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- Where
- 12 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 10,275 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company